Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States

被引:73
|
作者
Speicher, Paul J. [1 ]
Gu, Lin [2 ]
Gulack, Brian C. [1 ]
Wang, Xiaofei [2 ]
D'Amico, Thomas A. [1 ]
Hartwig, Matthew G. [1 ]
Berry, Mark F. [1 ,3 ]
机构
[1] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA
[3] Stanford Univ, Dept Cardiothorac Surg, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
Lobectomy; Lung cancer; NSCLC; Stage IA; Sublobar resection; SURVIVAL FOLLOWING LOBECTOMY; END RESULTS DATABASE; LIMITED RESECTION; TUMOR SIZE; WEDGE RESECTION; ELDERLY-PATIENTS; OUTCOMES; CM; SEGMENTECTOMY; EPIDEMIOLOGY;
D O I
10.1016/j.cllc.2015.07.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study evaluated the use of lobectomy and sublobar resection for clinical stage IA non-small-cell lung cancer (NSCLC) in the National Cancer Data Base. A total of 39,403 patients were included for analysis, of whom 9667 (24.5%) underwent sublobar resection. Lobectomy was associated with superior survival, however among sublobar resection patients, lymph node sampling was associated with improved outcomes although was performed in a minority of sublobar patients. This study emphasizes the need for nodal sampling when performing sublobar resection even for the earliest stages of NSCLC. Background: This study evaluated the use of lobectomy and sublobar resection for clinical stage IA non-small-cell lung cancer (NSCLC) in the National Cancer Data Base (NCDB). Methods: The NCDB from 2003 to 2011 was analyzed to determine factors associated with the use of a sublobar resection versus a lobectomy for the treatment of clinical stage IA NSCLC. Overall survival was assessed using the Kaplan-Meier method and Cox proportional hazard modeling. Results: Among 39,403 patients included for analysis, 29,736 (75.5%) received a lobectomy and 9667 (24.5%) received a sublobar resection: 84.7% wedge resection (n = 8192) and 15.3% segmental resection (n = 1475). Lymph node evaluation was not performed in 2788 (28.8%) of sublobar resection patients, and 7298 (75.5%) of sublobar resections were for tumors <= 2 cm. After multivariable logistic regression, older age, higher Charlson-Deyo comorbidity scores, smaller tumor size, and treatment at lower-volume institutions were associated with sublobar resection (all P < .001). Overall, lobectomy was associated with significantly improved 5-year survival compared to sublobar resection (66.2% vs. 51.2%; P < .001, adjusted hazard ratio 0.66; P < .001). However among sublobar resection patients, nodal sampling was associated with significantly better 5-year survival (58.2% vs. 46.4%; P < .001). Conclusion: Despite adjustment for patient and tumor related characteristics, a sublobar resection is associated with significantly reduced long-term survival compared to a formal surgical lobectomy among patients with NSCLC, even for stage 1A tumors. For patients who cannot tolerate lobectomy and who are treated with sublobar resection, lymph node evaluation is essential to help guide further treatment. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 50 条
  • [1] Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer
    Altorki, Nasser
    Wang, Xiaofei
    Kozono, David
    Watt, Colleen
    Landrenau, Rodney
    Wigle, Dennis
    Port, Jeffrey
    Jones, David R.
    Conti, Massimo
    Ashrafi, Ahmad S.
    Liberman, Moishe
    Yasufuku, Kazuhiro
    Yang, Stephen
    Mitchell, John D.
    Pass, Harvey
    Keenan, Robert
    Bauer, Thomas
    Miller, Daniel
    Kohman, Leslie J.
    Stinchcombe, Thomas E.
    Vokes, Everett
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (06): : 489 - 498
  • [2] Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer
    Lorenz, Judith
    ZENTRALBLATT FUR CHIRURGIE, 2023, 148 : S5 - S5
  • [3] Sublobar resection for stage IA non-small cell lung cancer
    Berfield, Kathleen S.
    Wood, Douglas E.
    JOURNAL OF THORACIC DISEASE, 2017, 9 : S208 - S210
  • [4] A nomogram to predict prognosis in patients undergoing sublobar resection for stage IA non-small-cell lung cancer
    Yang, Heli
    Li, Xiangdong
    Shi, Jialun
    Fu, Hao
    Yang, Hao
    Liang, Zhen
    Xiong, Hongchao
    Wang, Hui
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6611 - 6626
  • [5] Sublobar curative resection for non-small-cell lung cancer
    Bonnette, Pierre
    BULLETIN DU CANCER, 2012, 99 (11) : 1069 - 1075
  • [6] The Role of Sublobar Resection in Early-Stage Non-Small-Cell Lung Cancer
    Petrella, Francesco
    Cara, Andrea
    Cassina, Enrico Mario
    Degiovanni, Sara
    Libretti, Lidia
    Pirondini, Emanuele
    Raveglia, Federico
    Tuoro, Antonio
    Vaquer, Sara
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [7] Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer
    Fernando, HC
    Santos, RS
    Benfield, JR
    Grannis, FW
    Keenan, RJ
    Luketich, JD
    Close, JM
    Landreneau, RJ
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 129 (02): : 261 - 267
  • [8] Current Readings: Sublobar Resection for Non-Small-Cell Lung Cancer
    Donington, Jessica S.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2013, 25 (01) : 22 - 29
  • [9] Sublobar resection: an alternative to lobectomy in treating stage I non-small-cell lung cancer?
    Deng, Han-Yu
    Tang, Xiaojun
    Zhou, Qinghua
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2020, 57 (03) : 613 - 613
  • [10] Sublobar resection versus lobectomy in solid-type, clinical stage IA, non-small cell lung cancer
    Jeon, Hyun Woo
    Kim, Young-Du
    Kim, Kyung Soo
    Sung, Sook Whan
    Park, Hyung Joo
    Park, Jae Kil
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12